RecruitingPhase 3NCT07653100

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Sponsor

Pfizer

Enrollment

540 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

Respiratory Syncytial Virus (RSV)

Summary

The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Placebo and a biological treatment called RSVpreF for people with respiratory syncytial virus (rsv). The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALRSVpreF

RSVpreF Vaccine

BIOLOGICALPlacebo

Placebo

Locations(13)

King George Hospital

Visakhapatnam, Andhra Pradesh, India

BGS Global Institute of Medical Sciences (BGSGIMS)

Bangalore, Karnataka, India

Radhakrishna Multispeciality Hospital and IVF Center

Bangalore, Karnataka, India

Belagavi Institute of Medical Sciences - Belagavi

Belagavi, Karnataka, India

Suyog Hospital

Nashik, Maharashtra, India

Aakash Healthcare Private Limited

Dwarka, National Capital Territory of Delhi, India

All India Institute Of Medical Sciences

New Delhi, National Capital Territory of Delhi, India

Sir Ganga Ram Hospital

New Delhi, National Capital Territory of Delhi, India

Maharaja Agrasen Superspeciality Hospital

Jaipur, Rajasthan, India

SRM Medical College Hospital and Research Centre - Kattankulathur

Chengalpattu, Tamil Nadu, India

Chettinad Hospital and Research Institute

Kelambākkam, Tamil Nadu, India

Institute of Post Graduate Medical Education & Research, SSKM Hospital

Kolkata, West Bengal, India

Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital

Kolkata, West Bengal, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07653100

Related Trials

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

NCT07694557

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

NCT07768345

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

NCT07764237

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

NCT074826578 locations

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NCT068518066 locations